News
PTGX
25.22
-1.37%
-0.35
TURNSTONE BIOLOGICS APPOINTS WILLIAM WADDILL TO ITS BOARD OF DIRECTORS
Reuters · 2d ago
Weekly Report: what happened at PTGX last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at PTGX last week (0401-0405)?
Weekly Report · 04/08 11:23
All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy
NASDAQ · 04/05 16:00
Weekly Report: what happened at PTGX last week (0325-0329)?
Weekly Report · 04/01 11:20
Protagonist Therapeutics Earns ‘Buy’ Rating on Strong Clinical Progress and Strategic Partnerships
TipRanks · 03/27 10:05
Weekly Report: what happened at PTGX last week (0318-0322)?
Weekly Report · 03/25 11:23
Catalyst Watch: Walgreens earnings, UPS analyst day and Xiaomi's luxury EV debut
Seeking Alpha's Catalyst Watch looks at next week's key events. Options trading volume is elevated on Digital World Acquisition (DWAC) ahead of the potential listing of Trump Media & Technology. The Nevada Gaming Control Board report for February will be released. United Parcel Service (UPS) will hold its Analyst Day.
Seeking Alpha · 03/22 19:00
Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet
NASDAQ · 03/18 13:55
Weekly Report: what happened at PTGX last week (0311-0315)?
Weekly Report · 03/18 11:21
4 Stocks to Buy for Attractive Earnings Acceleration
NASDAQ · 03/15 10:13
AUR, CDLX and PTGX are among after hour movers
Seeking Alpha · 03/14 21:02
Protagonist Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.
Dow Jones · 03/11 16:23
Protagonist Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/11 16:23
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Maintains $38 Price Target
Benzinga · 03/11 16:15
Buy Rating Affirmed for Protagonist Therapeutics on Strong Phase 2b Results and Strategic Phase 3 Dosing of JNJ-2113
TipRanks · 03/11 16:05
Protagonist Therapeutics Price Target Maintained With a $42.00/Share by JMP Securities
Dow Jones · 03/11 14:23
JMP Securities Reiterates Market Outperform on Protagonist Therapeutics, Maintains $42 Price Target
Benzinga · 03/11 14:12
Protagonist Therapeutics Announced A Late-breaking Presentation At The American Academy Of Dermatology 2024 Annual Meeting With Results From The Phase 2b FRONTIER 2 Long-term Extension Study Evaluating JNJ-2113 For Moderate-to-severe Plaque Psoriasis
JNJ-2113 was jointly discovered and is being developed pursuant to a license and collaboration agreement between Protagonist and J&J. Protagonist retains exclusive worldwide rights to develop JNJ- 2113 in Phase 2 clinical trials and beyond. The companies worked together to discover and develop next-generation compounds.
Benzinga · 03/11 11:40
Weekly Report: what happened at PTGX last week (0304-0308)?
Weekly Report · 03/11 11:18
More
Webull provides a variety of real-time PTGX stock news. You can receive the latest news about Protagonist Ther through multiple platforms. This information may help you make smarter investment decisions.
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).